3 completed, 1 enrolling by invitation, 1 recruiting, 1 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Enrolling by invitation 1, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Pemphigoid, Bullous: new trials by email Literature Review of Pemphigoid, Bullous trials Research Report on Pemphigoid, Bullous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders BIV009, Placebo - Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD) | Phase 1 | Completed | Bioverativ, a Sanofi company | 122 | 2015-07-13 | 2022-04-25 |
| Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Rituximab - Ocular Cicatricial Pemphigoid | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 3 | 2006-01-01 | 2026-05-04 |
| Rituximab in the Treatment of Patients With Bullous Pemphigoid Rituximab - Bullous Pemphigoid | Phase 1 / Phase 2 | Completed | Duke University | 8 | 2005-03-01 | 2013-04-11 |
Antiphospholipid Syndrome (2) · Behcet Syndrome (2) · Dermatomyositis (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Anemia, Hemolytic, Autoimmune (1) · Blindness (1) · Kidney Failure, Chronic (1) · Pemphigoid, Benign Mucous Membrane (1) · Stevens-Johnson Syndrome (1)
Autoimmune Diseases (6) · Immune System Diseases (6) · Skin Diseases (6) · Skin Diseases, Vesiculobullous (6) · Skin and Connective Tissue Diseases (6) · Pathological Conditions, Signs and Symptoms (4) · Eye Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Mouth Diseases (3) · Nervous System Diseases (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Stomatognathic Diseases (3) · Blood Coagulation Disorders (2)
Rituximab (2) · Saline Solution (1)
Chugai Pharmaceutical (2) · Bioverativ, a Sanofi company (1) · Duke University (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · University of Alabama at Birmingham (1)
Austria (3) · Spain (3) · United States (3) · Australia (2) · Bulgaria (2) · Canada (2) · Croatia (2) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Japan (2) · Netherlands (2) · Norway (2)
Craig A Elmets (1) · Russell Hall, III, MD (1)
PMID 27716293, PMID 28926521, PMID 28980446, PMID 30559259, PMID 38995690
2014 (1)